UROLOGIC CANCER
Clinical trials for UROLOGIC CANCER explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC CANCER trials appear
Sign up with your email to follow new studies for UROLOGIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer drug trial halted before it began
Disease control TerminatedThis study was designed to test whether a new drug called NDV-01 (a slow-release combination of two chemotherapy medicines) could prevent bladder cancer from coming back after surgery. It planned to enroll 302 people with intermediate-risk non-muscle invasive bladder cancer. Howe…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 01:29 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis study was designed to test a new drug combination (NDV-01) given directly into the bladder for people with a type of early bladder cancer that did not respond to standard BCG treatment. The goal was to see if the drug could make the cancer disappear. However, the trial was w…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Bladder cancer virus therapy aims to stop tumors from returning
Disease control OngoingThis study tests whether a virus-based treatment called cretostimogene grenadenorepvec can prevent bladder cancer from returning after surgery. About 367 people with intermediate-risk non-muscle invasive bladder cancer will either receive the treatment or be watched closely. The …
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC